Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab · Moderate to Severe HS Within the Italian Population Trial sites expanded: 16 → 22 locations Novartis PharmaceuticalsNot specified NCT07543419
  2. Minor: NIS Evaluating Various Injectable and Oral Treatments · Relapsing Multiple Sclerosis Trial sites expanded: 141 → 146 locations Novartis PharmaceuticalsNot specified NCT05344469
  3. Minor: Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia Trial sites expanded: 42 → 49 locations Novartis PharmaceuticalsNot specified NCT06930859
  4. Minor: Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery · Early-stage, Operable, Non-small Cell Lung Cancer Trial sites expanded: 42 → 45 locations ETOP IBCSG Partners FoundationPhase 3 NCT06284317
  5. Minor: Biomarker Targeted Stimulation for Epileptiform Events Trial sites expanded: 0 → 4 locations Cadence NeuroscienceNot applicable NCT06424977
  6. Minor: VitaSmart HOPE System: Bridge to HOPE Registry Trial sites expanded: 1 → 9 locations Bridge to Life Ltd.Not specified NCT07578441
  7. Minor: Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit Enrollment increased: 954 → 1054 participants Centre Hospitalier Régional Metz-ThionvilleNot applicable NCT05475574
  8. Minor: Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients Enrollment increased: 300 → 400 participants University of UtahNot specified NCT06875700
  9. Minor: Canadian Critical Care Comparative Effectiveness Platform Trial sites expanded: 11 → 14 locations Université de SherbrookePhase 3 NCT06605144
  10. Minor: Inclisiran Versus Placebo · Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention Trial sites expanded: 149 → 153 locations Duke UniversityPhase 4 NCT06909565
  11. Minor: Monotherapy With P2Y12 Inhibitors · Atrial fIbrillation Undergoing Drug-eluting Stent Implantation Trial sites expanded: 15 → 18 locations Insel Gruppe AG, University Hospital BernPhase 4 NCT05955365
  12. Minor: European Disease Registry on Retinopathy of Prematurity (ROP) Trial sites expanded: 59 → 79 locations University Medicine GreifswaldNot specified NCT04939571
  13. Minor: Cardiogenic Shock Working Group Registry Trial sites expanded: 16 → 22 locations Tufts Medical CenterNot specified NCT04682483
  14. Minor: Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets · Overweight or Obesity Interventions modified Hangzhou Sciwind Biosciences Co., Ltd.Phase 1/2 NCT07243171
  15. Minor: Effects and Safety of RO7568282 in Early Parkinson's Disease Start date changed from estimate of Nov 10, 2026 to Nov 11, 2026 Hoffmann-La RochePhase 2 NCT07781644
  16. Minor: Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe Trial sites expanded: 44 → 48 locations University Medical Center GroningenNot specified NCT07585890
  17. Minor: PF-08098488 · Advanced Solid Tumors Start date changed from estimate of Oct 29, 2026 to Nov 5, 2026 PfizerPhase 1 NCT07903415
  18. Minor: Novel Ocular Lubricating Eye Drop Study completion moved earlier from May 2027 to Feb 2027 Pleryon Therapeutics (Hangzhou) LimitedNot applicable NCT07593404
  19. Minor: Anti-cancer Drug Darolutamide · Testosterone-Driven Salivary Gland Cancers Study completion pushed from Nov 30, 2026 to Nov 12, 2027 National Cancer Institute (NCI)Phase 2 NCT05669664
  20. Minor: Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy Study completion pushed from Nov 30, 2026 to Nov 12, 2027 National Cancer Institute (NCI)Early Phase 1 NCT04494113
  21. Minor: Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders Start date changed from estimate of Nov 18, 2026 to Nov 10, 2026 National Institute of Allergy and Infectious Diseases (NIAID)Not specified NCT07683104
  22. Minor: Comparative Evaluation of Alb PRF Versus Connective Tissue Graft in Reconstruction of Deficient Interdental Papilla Study completion moved earlier from Dec 20, 2028 to Dec 22, 2027 ahmed mostafa ahmed abo el soudPhase 3 NCT07597135
  23. Minor: Niraparib in Combination With Dostarlimab · Recurrent or Progressive Cervix Cancer Primary completion date changed from estimate of Dec 2026 to Aug 6, 2026 University of OklahomaPhase 2 NCT04068753
  24. Minor: TiUltra Implant Study Interventions modified University of Maryland, BaltimorePhase 4 NCT07911319
  25. Minor: Enhancing the Effect of Stellate Ganglion Block · PTSD: Bupivacaine vs Bupivacaine + Ketamine Interventions modified The Royal's Institute of Mental Health ResearchPhase 2 NCT07927036